Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association - 1 Sept 2023

Li Shujing, Zhao Sien, Liang Nianhai, Zhang Shaoting, Zhang Liangying, Zhou Liangji, Liu Anbu, Cao Xu, Tian Jinhai, Yu Yuanyuan, Fan Zhaoyang, Xiao Kun, Wang Ming, Zhao Hui, Bai Ru, Sun Jianmin

Abstract excerpt

BACKGROUND: KIT is frequently mutated in gastrointestinal stromal tumors (GISTs), and the treatment of GISTs largely relies on targeting KIT currently. In this study, we aimed to investigate the role of sprouty RTK signaling antagonist 4 (SPRY4) in GISTs and related mechanisms. METHODS: Ba/F3 cells and GIST-T1 cell were used as cell models, and mice carrying germline KIT/V558A mutation were used as animal model....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Stomach Neoplasms

Source

Identifiers

PMID: 37222910
DOI: 10.1007/s10120-023-01402-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib.PMID 37222910Read ↗

RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor.Semantic proximity Read ↗

BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor.Semantic proximity Read ↗

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.Semantic proximity Read ↗

DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors.Semantic proximity Read ↗

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.Semantic proximity Read ↗

KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.Semantic proximity Read ↗

Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.Semantic proximity Read ↗

SHP2 inhibition and adjuvant therapy synergistically target KIT-mutant GISTs via ERK1/2-regulated GSK3β/cyclin D1 pathway.Semantic proximity Read ↗

Imatinib treatment for gastrointestinal stromal tumour (GIST).Semantic proximity Read ↗

[Molecular mechanisms of primary and secondary resistance, molecular-genetic features and characteristics of KIT/PDGFRA non-mutated GISTs].Semantic proximity Read ↗

Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.